SIM0916
Phase 3Small molecule
SIM0916 is one of 48 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Busulfex
Akero TherapeuticsPhase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Alka-Seltzer
AAbbott
Phase 3
Oxycontin
PPurdue Pharma LP
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Tpoxx
SSIGA Technologies
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SIM0916. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSimcere Pharmaceutical Co., Ltd